Managing Primary Biliary Cholangitis Progression and Symptoms — Though only one approved agent has been available for decades, the armamentarium has expanded ...

Primary biliary cholangitis (PBC) can deliver a significant blow to patients' quality of life, especially if they are not appropriately diagnosed and treated.

The table below is a review of notable updates that occurred in June 2025 for investigational products in development (not an inclusive list). Click on ...

Primary sclerosing cholangitis (PSC) affects the liver and bile ducts. Symptoms and treatment vary from person to person. PSC is a rare liver disease that affects the bile ducts.

FDA approves Ipsen's Iqirvo for primary biliary cholangitis, ending a 10-year hiatus in new therapies for the rare cholestatic liver disease.

Once clinical suspicion has been established for primary biliary cholangitis (PBC), the "serologic hallmark" of the autoimmune disease are anti-mitochondrial antibodies (AMA), present in ...

FDA approves Gilead's Livdelzi for primary biliary cholangitis, setting up a contest with Ipsen's recent launch Iqirvo in the second-line setting.

Primary biliary cholangitis is a chronic autoimmune disease critically linked to immunological dysregulation but the local immune-pathogenesis is poorly understood.

Edith Pritchett attended the University of Edinburgh and graduated with a degree in Fine Art. From 2018 to 2021 she was the in-house cartoonist for Tortoise Media. Since 2021, she has been ...